Form 4: Vaxart CEO Steven Lo Receives Stock Grants and Options
SEC Form 4 Filing
Vaxart's CEO, Steven Lo, was granted 250,000 shares of common stock and options to purchase 1,000,000 shares on March 18, 2024.
Summary
- On March 18, 2024, Steven Lo, the President and CEO of Vaxart, Inc., received 250,000 shares of common stock upon the vesting of restricted stock units.
- These shares vest 25% annually, starting March 18, 2024, and will be fully vested by the fourth anniversary.
- Lo was also granted an option to purchase 1,000,000 shares of common stock at an exercise price of $1.16.
- The options vest 25% on March 18, 2025, and then in 36 equal monthly installments, becoming fully vested on March 18, 2028.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grants align the CEO's interests with shareholders, which is generally viewed positively, but it's not a major event.
Positives
- The vesting of stock and options for the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Future Outlook
The document does not contain specific forward-looking statements about the company's performance, but the vesting schedule suggests a long-term commitment from the CEO.
Industry Context
Stock grants and options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages in the biotech industry typically include a mix of salary, stock options, and restricted stock units.
- The size and vesting schedule of these grants are often benchmarked against peer companies of similar size and stage of development.
- For example, companies like Novavax and Moderna also use stock options and restricted stock units as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock and option grants as a positive sign, aligning management's interests with the company's long-term success.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/18/2024 | Date of transaction: Grant of shares and stock options to Steven Lo. |
| 03/18/2025 | First vesting anniversary for both the restricted stock units and the stock options (25% vesting). |
| 03/18/2028 | Date the stock options are fully vested. |
| 03/17/2034 | Expiration date of the stock options. |
| 03/20/2024 | Date of filing of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.